Turkiye Klinikleri Journal of Dermatology

.: ORIGINAL RESEARCH
Vitiligo Hastalarında Serum C-Reaktif Protein/Albumin Oranının Değerlendirilmesi: Retrospektif Vaka Kontrol Çalışması
Assessment of the Serum C-Reactive Protein/Albumin Ratio in Patients with Vitiligo: A Retrospective Case-Control Study
Bülent Nuri KALAYCIa
aMalatya Turgut Özal Üniversitesi Tıp Fakültesi, Dermatoloji ABD, Malatya, Türkiye
Turkiye Klinikleri J Dermatol. 2023;33(2):60-6
doi: 10.5336/dermato.2022-94816
Article Language: TR
Full Text
ÖZET
 Amaç: Vitiligo etiyopatogenezinde sistemik inflamasyon önemli rol oynar. Birçok inflamatuar hastalık için serum C-reaktif protein (CRP)/albumin oranı [C-reactive protein/albumin ratio (CAR)] prognostik belirteç olarak bildirilmektedir. Vitiligo hastalarında ve sağlıklı kontrollerde CAR değerinin belirlenerek, vitiligo şiddeti ve aktivitesi ile ilişkisinin araştırılmasını amaçladık. Gereç ve Yöntemler: Hastanemizde vitiligo tanısı konulmuş 78 hasta ile benzer yaş ve cinsiyette 78 sağlıklı kontrol retrospektif olarak çalışmaya alındı. Hastalık şiddetini belirlemek için Vitiligo Alan ve Şiddet İndeksi kullanıldı. Vitiligo Hastalık Aktivite Skoru [Vitiligo Disease Activity Score (VIDA)] baz alınarak, hastalar aktif ve stabil olarak 2 grupta incelendi. Hasta ve kontrol grubu için serum CRP ve serum albumin değerleri oranlanarak CAR değeri hesaplandı. Bulgular: Çalışmadaki 78 hastanın 30'u (%38) erkek, 48'i (%62) kadın; yaş ortalaması 33±8,9 idi. Kontrol grubunun 32'si (%41) erkek, 46'sı (%59) kadın; yaş ortalaması 35,8±9,7 idi (p>0,05). Serum CRP düzeyi hasta grubunda ortalama 0,82±0,44 mg/dL iken, sağlıklı kontrollerde 0,31±0,17 mg/dL olarak bulundu (p=0,001). Ortalama CAR değeri hasta grubunda 0,21±0,12, sağlıklı kontrollerde 0,07±0,04 olarak bulundu (p=0,001). VIDA skoru ile CAR değeri (r=0,54; p<0,01) arasında ve VIDA skoru ile CRP değeri (r=0,47; p<0,01) arasında pozitif korelasyon mevcuttu. CAR için kesme değeri (cut off) %78 sensitivite ve %80 spesifite ile 0,2 idi. Sonuç: CAR değeri, vitiligoda sistemik inflamasyonun ve hastalık aktivitesinin bir göstergesi olabilir.

Anahtar Kelimeler: Vitiligo; C-reaktif protein; albumin; C-reaktif protein/albumin oranı
ABSTRACT
 Objective: Systemic inflammation plays a significant role in the etiopathogenesis of vitiligo. The serum C-reactive protein (CRP)/albumin ratio (CAR) has been reported as an important prognostic marker in many inflammatory diseases. To determine the CAR value in patients with vitiligo and healthy controls and investigate the relationship of this parameter with vitiligo severity and activity. Material and Methods: Seventy-eight patients diagnosed with vitiligo in our hospital and 78 age- and gender-matched healthy controls were retrospectively included in the study. Disease severity was assessed using the Vitiligo Area and Severity Index. The Vitiligo Disease Activity Score (VIDA) was used to determine disease activity. The CAR value was calculated by dividing the serum CRP values by the serum albumin values for the patient and control groups. Results: Of the 78 patients with vitiligo in these study, 30 (38%) were male and 48 (62%) were female, and their mean age was 33±8.9 years. In the healthy controls, 32 (41%) participants were male and 46 (59%) were female, with a mean age of 35.8±9.7 years (p>0.05). The serum CRP level was mean 0.82±0.44 mg/dL in the vitiligo group and 0.31±0.17 mg/dL in the controls (p=0.001). The mean CAR values of the vitiligo was 0.21±0.12 and healthy controls was 0.07±0.04 (p=0.001). A positive correlation was observed between the VIDA score and CAR (r=0.54; p<0.01) and CRP (r=0.47; p<0.01). The CAR cut-off value was calculated as 0.2 with 78% sensitivity and 80% specificity. Conclusion: The CAR value may be indicative of systemic inflammation and disease activity in vitiligo.

Keywords: Vitiligo; C-reactive protein; albumin; C-reactive protein/albumin ratio
REFERENCES:
  1. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65(3):473-91. [Crossref]  [PubMed] 
  2. Taïeb A, Picardo M; VETF Members. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res. 2007;20(1):27-35. [Crossref]  [PubMed] 
  3. Halder RM, Chappell JL. Vitiligo update. Semin Cutan Med Surg. 2009;28(2):86-92. [Crossref]  [PubMed] 
  4. Sandoval-Cruz M, García-Carrasco M, Sánchez-Porras R, Mendoza-Pinto C, Jiménez-Hernández M, Munguía-Realpozo P, et al. Immunopathogenesis of vitiligo. Autoimmun Rev. 2011;10(12):762-5. [Crossref]  [PubMed] 
  5. Zhen Y, Yao L, Zhong S, Song Y, Cui Y, Li S. Enhanced Th1 and Th17 responses in peripheral blood in active non-segmental vitiligo. Arch Dermatol Res. 2016;308(10):703-10. [Crossref]  [PubMed] 
  6. Solak B, Dikicier BS, Cosansu NC, Erdem T. Neutrophil to lymphocyte ratio in patients with vitiligo. Postepy Dermatol Alergol. 2017;34(5):468-70. [Crossref]  [PubMed]  [PMC] 
  7. Yasmin T, Aya B, Amal H, Amira K, Ahmed G. Serum interleukin-22 and C-reactive protein in patients with vitiligo: a case-control study on 35 Egyptian patients. Egypt J Dermatol Venerol. 2021;41(1):32-7. [Crossref] 
  8. Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol. 2004;140(6):677-83. [Crossref]  [PubMed] 
  9. Njoo MD, Das PK, Bos JD, Westerhof W. Association of the Köbner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris. Arch Dermatol. 1999;135(4):407-13. [Crossref]  [PubMed] 
  10. Demirbaş A, Elmas ÖF, Atasoy M, Türsen Ü, Lotti T. Can monocyte to HDL cholesterol ratio and monocyte to lymphocyte ratio be markers for inflammation and oxidative stress in patients with vitiligo? A preliminary study. Arch Dermatol Res. 2021;313(6):491-8. [Crossref]  [PubMed] 
  11. Acharya P, Mathur M. Interleukin-17 level in patients with vitiligo: A systematic review and meta-analysis. Australas J Dermatol. 2020;61(2):e208-e12. [Crossref]  [PubMed] 
  12. Tomaszewska K, Kozłowska M, Kaszuba A, Lesiak A, Narbutt J, Zalewska-Janowska A. Increased serum levels of IFN-γ, IL-1β, and IL-6 in patients with alopecia areata and nonsegmental vitiligo. Oxid Med Cell Longev. 2020;2020:5693572. [Crossref]  [PubMed]  [PMC] 
  13. Castell JV, Gómez-Lechón MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990;12(5):1179-86. [Crossref]  [PubMed] 
  14. Holt I, Cooper RG, Hopkins SJ. Relationships between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients. Eur J Clin Invest. 1991;21(5):479-84. [Crossref]  [PubMed] 
  15. Póvoa P, Coelho L, Almeida E, Fernandes A, Mealha R, Moreira P, et al. C-reactive protein as a marker of infection in critically ill patients. Clin Microbiol Infect. 2005;11(2):101-8. [Crossref]  [PubMed] 
  16. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805-12. Erratum in: J Clin Invest. 2003;112(2):299. [Crossref]  [PubMed]  [PMC] 
  17. Beygi S, Lajevardi V, Abedini R. C-reactive protein in psoriasis: a review of the literature. J Eur Acad Dermatol Venereol. 2014;28(6):700-11. [Crossref]  [PubMed] 
  18. Georgescu SR, Ene CD, Tampa M, Matei C, Benea V, Nicolae I. Oxidative stress- related markers and alopecia areata through latex turbidimetric immunoassay method. Mater. Plast. 2016;53(3):522-6. [Link] 
  19. Vekaria AS, Brunner PM, Aleisa AI, Bonomo L, Lebwohl MG, Israel A, et al. Moderate-to-severe atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activity. F1000Res. 2017;6:1712. [Crossref]  [PubMed]  [PMC] 
  20. Don BR, Kaysen G. Serum albumin: relationship to inflammation and nutrition. Semin Dial. 2004;17(6):432-7. [Crossref]  [PubMed] 
  21. Cabrerizo S, Cuadras D, Gomez-Busto F, Artaza-Artabe I, Marín-Ciancas F, Malafarina V. Serum albumin and health in older people: Review and meta analysis. Maturitas. 2015;81(1):17-27. [Crossref]  [PubMed] 
  22. Alves FC, Sun J, Qureshi AR, Dai L, Snaedal S, Bárány P, et al. The higher mortality associated with low serum albumin is dependent on systemic inflammation in end-stage kidney disease. PLoS One. 2018;13(1):e0190410. [Crossref]  [PubMed]  [PMC] 
  23. Sheikh G, Masood Q, Majeed S, Hassan I. Comparison of levels of serum copper, zinc, albumin, globulin and alkaline phosphatase in psoriatic patients and controls: A hospital based casecontrol study. Indian Dermatol Online J. 2015;6(2):81-3. [Crossref]  [PubMed]  [PMC] 
  24. Li WC, Mo LJ, Shi X, Lin ZY, Li YY, Yang Z, et al. Antioxidant status of serum bilirubin, uric acid and albumin in pemphigus vulgaris. Clin Exp Dermatol. 2018;43(2):158-63. [Crossref]  [PubMed] 
  25. Park JE, Chung KS, Song JH, Kim SY, Kim EY, Jung JY, et al. The C-reactive protein/albumin ratio as a predictor of mortality in critically ill patients. J Clin Med. 2018;7(10):333. [Crossref]  [PubMed]  [PMC] 
  26. Ranzani OT, Zampieri FG, Forte DN, Azevedo LC, Park M. C-reactive protein/albumin ratio predicts 90-day mortality of septic patients. PLoS One. 2013;8(3):e59321. [Crossref]  [PubMed]  [PMC] 
  27. Fu YJ, Li KZ, Bai JH, Liang ZQ. C-reactive protein/albumin ratio is a prognostic indicator in Asians with pancreatic cancers: A meta-analysis. Medicine (Baltimore). 2019;98(48):e18219. [Crossref]  [PubMed]  [PMC] 
  28. Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Shibuya N, Kubota K. Clinical significance of the c-reactive protein to albumin ratio for survival after surgery for colorectal cancer. Ann Surg Oncol. 2016;23(3):900-7. [Crossref]  [PubMed] 
  29. Ni XF, Wu J, Ji M, Shao YJ, Xu B, Jiang JT, et al. Effect of C-reactive protein/albumin ratio on prognosis in advanced non-small-cell lung cancer. Asia Pac J Clin Oncol. 2018;14(6):402-9. [Crossref]  [PubMed] 
  30. Qin G, Tu J, Liu L, Luo L, Wu J, Tao L, et al. Serum albumin and c-reactive protein/albumin ratio are useful biomarkers of crohn's disease activity. Med Sci Monit. 2016;22:4393-400. [Crossref]  [PubMed] 
  31. Slouma M, Rahmouni S, Dhahri R, Gharsallah I, Metoui L, Louzir B. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, c-reactive protein to albumin ratio, and albumin to fibrinogen ratio in axial spondyloarthritis: a monocentric study. Curr Rheumatol Rev. 2021;17(3):312-7. [Crossref]  [PubMed] 
  32. Seringec Akkececi N, Yildirim Cetin G, Gogebakan H, Acipayam C. The c-reactive protein/albumin ratio and complete blood count parameters as indicators of disease activity in patients with Takayasu Arteritis. Med Sci Monit. 2019;25:1401-9. [Crossref]  [PubMed]  [PMC] 
  33. Kayabasi S, Hizli O, Cayir S. A novel predictor parameter for active recurrent aphthous stomatitis: c-reactive protein to albumin ratio. Cureus. 2019;11(10):e5965. [Crossref]  [PubMed]  [PMC] 
  34. Kemeriz F, Tuğrul B, Tuncer SÇ. C-reactive protein to albumin ratio: Is a new parameter for the disease severity in patients with psoriasis vulgaris? Dermatologica Sinica. 2020;38(4):199-204. [Crossref] 
  35. Tamer F, Avcı E. Serum C-reactive protein to albumin ratio as a novel inflammation biomarker in psoriasis patients treated with adalimumab, ustekinumab, infliximab, and secukinumab: a retrospective study. Croat Med J. 2020;61(4):333-7. [Crossref]  [PubMed]  [PMC] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com